← Research goals

Lean mass and growth-hormone signaling

What the published literature pairs among growth-hormone-signaling compounds, graded by how strong the pairing evidence is.

Graded pairings

Mentioned together

BPC-157 and CJC-1295

Named together in the same review articles, but never tested together. We say that plainly here, and show why researchers list them side by side.

Open →
Mentioned together

BPC-157 and Ipamorelin

Named together in the same review articles, but never tested together. We say that plainly here, and show why researchers list them side by side.

Open →
Co-administered

CJC-1295 and Ipamorelin

A growth-hormone secretagogue pairing. One murine study has given both together; the human evidence is not there yet.

Open →
Mentioned together

CJC-1295 and TB-500

Named together in the same review articles, but never tested together. We say that plainly here, and show why researchers list them side by side.

Open →
Mentioned together

Ipamorelin and TB-500

Named together in the same review articles, but never tested together. We say that plainly here, and show why researchers list them side by side.

Open →

Reading this goal in one minute

Of the five pairings here, only CJC-1295 and Ipamorelin has a co-administered grade, and that rests on one murine study. The other four are only mentioned together: reviews name them side by side, and no study has given them together.

On the compounds themselves:

  • Tesamorelin is the one FDA-approved compound in the atlas, cleared for a specific HIV-related use.
  • CJC-1295 has two early human trials that measured hormone levels.
  • Ipamorelin has animal outcome data, plus two completed human trials that report status and title only.

Our grade definitions explain why a review mention never counts as combined evidence. The interaction checker shows our mechanism reading for any pair.